MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jpeds.2022.06.005

Медицинская библиотека · The Journal of pediatrics · 2022

Longitudinal Natural History of Pediatric Subjects Affected with Mucopolysaccharidosis IIIB.

Okur Ilyas, Ezgu Fatih, Giugliani Roberto, Muschol Nicole, Koehn Anja, Amartino Hernan, Harmatz Paul, de Castro Lopez Maria J, Couce Maria Luz, Lin Shuan-Pei, Batzios Spyros, Cleary Maureen, Solano Martha, Peters Heidi, Lee Joy, Nestrasil Igor, Shaywitz Adam J, Maricich Stephen M, Kuca Bernice, Kovalchin Joseph, Zanelli Eric

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

To characterize the longitudinal natural history of disease progression in pediatric subjects affected with mucopolysaccharidosis (MPS) IIIB.

STUDY

DESIGN

Sixty-five children with a confirmed diagnosis of MPS IIIB were enrolled into 1 of 2 natural history studies and followed for up to 4 years. Cognitive and adaptive behavior functions were analyzed in all subjects, and volumetric magnetic resonance imaging analysis of liver, spleen, and brain, as well as levels of heparan sulfate (HS) and heparan sulfate nonreducing ends (HS-NRE), were measured in a subset of subjects.

RESULTS

The majority of subjects with MPS IIIB achieved an apex on both cognition and adaptive behavior age equivalent scales between age 3 and 6 years. Development quotients for both cognition and adaptive behavior follow a linear trajectory by which subjects reach a nadir with a score <25 for an age equivalent of 24 months by age 8 years on average and by 13.5 years at the latest. All tested subjects (n = 22) had HS and HS-NRE levels above the normal range in cerebrospinal fluid and plasma, along with signs of hepatomegaly. Subjects lost an average of 26 mL of brain volume (-2.7%) over 48 weeks, owing entirely to a loss of cortical gray matter (32 mL; -6.5%).

CONCLUSIONS

MPS IIIB exists along a continuum based on cognitive decline and cortical gray matter atrophy. Although a few individuals with MPS IIIB have an attenuated phenotype, the majority follow predicted trajectories for both cognition and adaptive behavior.

TRIAL REGISTRATION: ClinicalTrials.gov identifiers NCT02493998, NCT03227042, and NCT02754076.

Для цитирования: Okur Ilyas, Ezgu Fatih, Giugliani Roberto, Muschol Nicole, Koehn Anja, Amartino Hernan, Harmatz Paul, de Castro Lopez Maria J, Couce Maria Luz, Lin Shuan-Pei, Batzios Spyros, Cleary Maureen, Solano Martha, Peters Heidi, Lee Joy, Nestrasil Igor, Shaywitz Adam J, Maricich Stephen M, Kuca Bernice, Kovalchin Joseph, Zanelli Eric. Longitudinal Natural History of Pediatric Subjects Affected with Mucopolysaccharidosis IIIB.. The Journal of pediatrics. 2022. DOI: 10.1016/j.jpeds.2022.06.005.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.